siltuximab + bortezomib + dexamethasone

Siltuximab + bortezomib + dexamethasone is a combination regimen investigated primarily for the treatment of multiple myeloma and other plasma cell disorders. Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing its interaction with both soluble and membrane-bound IL-6 receptors, thereby inhibiting downstream pro-inflammatory and proliferative signaling. Bortezomib is a reversible inhibitor of the 26S proteasome, disrupting protein degradation pathways essential for cancer cell survival. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, commonly used in hematologic malignancies to induce apoptosis in lymphoid cells. The combination has been studied in relapsed/refractory multiple myeloma, showing potential synergistic effects by targeting different aspects of tumor biology[2][4][8].

Other names

siltuximabbortezomibdexamethasone